Top Companies To Buy For 2014


If you could build your own mutual fund, what would it include?

Andrew Rogers heads a firm that allows advisors to do just that. The CEO of Gemini Fund Services says it helps with all aspects of starting a pooled investment product as well as converting existing funds.

Rogers is seeing three areas of growth, all involving alternative investments. The first is a big uptick in interest in “the hedge fund to mutual fund conversion,” particularly with so-called multi-strategy products.


“The JOBS Act now allows hedge funds to advertise,” he notes. “This is ultimately, I think, a good thing because they can now promote their performance, and advisors can show clients how well certain strategies that they now have access to are performing.”

Top Companies To Buy For 2014: Valeant Pharmaceuticals International Inc(VRX)

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders; Xenazine to treat chorea associated with Huntington?s disease; CeraVe to rebuild and repair skin barrier; and Kinerase, a cosmetic product. The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea and vomiting associated with cancer chemotherapy; Tiazac XC to treat hypertension and angina; Wellbutrin to treat depressive illness; Sublinox to treat insomnia; and Lodalis to treat hypercholesterolemia. Further, the company provides Cold-FX to strengthen immune system; Duromine/Metermine for weight loss; Difflam to treat sore throa ts; and Duro-Tuss and Rikodeine to treat dry and chesty cough, as well as various branded generics for treatments, including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications, and diabetic therapies. Additionally, it offers Bisocard to treat hypertension and angina pectoris; Flucinar, a corticosteroid ointment; and Sachol mouth ulcer gel; Bedoyecta to treat neurotic pain; M.V.I., a hospital dietary supplement for trauma and burns; Tandene to treat fever and headache; Melleril to treat anxiety and depression; and products for therapeutic classes, such as vitamin deficiency, antibacterials, and dermatology. It markets its products in the United States, Canada, Australia, New Zealand, Europe, Latin America, southeast Asia, and South Africa. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1960 and is headquartered in M ississauga, Canada.


Advisors’ Opinion:

  • [By ETF Authority]

    Valeant Pharmaceuticals(VRX) is a specialty pharmaceutical company, designing drugs for central nervous system disorders. It also has an over-the-counter business in Australia and branded drug operations in Latin America and Eastern Europe.

    Potiga, an epilepsy medication, is in the final stage of approval and expected to launch in the U.S. and Europe in 2011. Jefferies boosted its price target for Valeant to $50 on Jan. 7, following the company’s 2011 guidance, which entailed expectation of a substantially lower tax rate for the full-year 2011.


    Jefferies expects the stock to garner much attention in 2011 on mergers and acquisition deals and continued above-peer growth rates. Valeant’s stock has delivered annualized gains of 39% over a three-year span. It is not an equity without risk, though. The company suffered a GAAP loss of $208 million, or $1.27 a share, in the third quarter. Furthermore, it sells for a cash flow multiple of 21, a 68% premium to the phar maceutical industry average. Failure to achieve expected costs synergies from the Biovail merger is a risk.

    Bullish Scenario: Jefferies expects Valeant to climb 25% to $50.


    Bearish Scenario: Goldman Sachs forecasts a fall of 13% to $34.

Top Companies To Buy For 2014: NET Servicos de Comunicacao S.A.(NETC)

Net Servicos de Comunicacao S.A., through its subsidiaries, provides cable television, Internet access, and voice services in Brazil. It offers cable television services under the ?NET? brand name through various cable networks located in the largest cities of Brazil. The company also offers broadband Internet access services under the ?NET VIRTUA? brand name by using Embratel’s IP backbone infrastructure. In addition, it provides voice services under the ?NET FONE VIA EMBRATEL? brand name jointly with Embratel. Further, the company offers integrated video, broadband, and voice services. Net Servicos de Comunicacao S.A. was founded in 1994 and is headquartered in Sao Paulo, Brazil.

Top Companies To Buy For 2014: Shaw River Resources Ltd(SRR.AX)


Shaw River Manganese Limited engages in the exploration and development of manganese projects in Australia, Ghana, and Namibia. It holds interests in the Otjozondu project located in Namibia; the Baramine project located in Pilbara, Western Australia; and the Butre project located in Ghana. The company was formerly known as Shaw River Resources Limited and changed its name to Shaw River Manganese Limited in May 2011. Shaw River Manganese Limited is based in West Perth, Australia.

Top Companies To Buy For 2014: Dixons Grp (DXNS.L)

Dixons Group